Floatz logo

Tislelizumab

Solid Tumor, Unspecified, Adult

Hutchmedmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Solid Tumor, Unspecified, Adult cohort.

Asset / SponsorPhaseRating
Fruquintinib
Hutchmed
Phase 1/2CCC
Mpb-1734
MegaPro Biomedical Co. Ltd.
Phase 1/2CCC
rc48-adc
Hutchmed
Phase 1/2CCC
Pyrotinib
Hutchmed
Phase 1/2CCC
ad1208
Avelos Therapeutics Inc.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →